Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced it has signed an exclusive distribution agreement with Roche for the multi-country commercialization of Senseonics’ Eversense® Continuous Glucose Monitoring System.